Pneumococcal polysaccharide vaccine (PPSV23)

Routine vaccination:
    • Minimum age: 2 years
    • Not recommended for routine use in healthy individuals. Recommended only for the vaccination of persons with certain high-risk conditions.
    • Administer PPSV at least 8 weeks after the last dose of PCV to children aged 2 years or older with certain underlying medical conditions like anatomic or functional asplenia (including sickle cell disease), HIV infection, cochlear implant or cerebrospinal fluid leak.
    • An additional dose of PPSV should be administered after 5 years to children with anatomic/functional asplenia or an immunocompromising condition.
    • PPSV should never be used alone for prevention of pneumococcal diseases amongst high–risk individuals.
    • Children with following medical conditions for which PPSV23 and PCV13 are indicated in the age group 24 through 71 months:
      • Immunocompetent children with chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus; cerebrospinal fluid leaks; or cochlear implant.
      • Children with anatomic or functional asplenia (including sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction);
      • Children with immunocompromising conditions: HIV infection, chronic renal failure and nephrotic syndrome, diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas and Hodgkin disease; or solid organ transplantation, congenital immunodeficiency.